Evidence map›Paper›PMID 35850404›Full record

ReviewPharmacology & therapeutics2022

Game of clones: Battles in the field of carcinogenesis.

Zahraa Rahal, Ansam Sinjab, Ignacio I Wistuba, Humam Kadara

Erratum issuedOpen access · greenAbstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. EarlybioRxiv : the preprint server for biology · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zahraa RahalDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, USA.
Ansam SinjabDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, USA.
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, USA. Electronic address: hkadara@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancerR01CA272863 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Humam Kadara, Seyed Javad Mirhassani Moghaddam · 2022 to 2026
$2.9M
Translational Genomics and Precision Medicine in Cancer Training ProgramT32CA217789 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Subrata Sen · 2018 to 2026
$2.2M
Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma developmentU01CA264583 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Humam Kadara, Linghua Wang · 2022 to 2026
$2.1M
NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA272863NCI NIH HHS T32 CA217789NCI NIH HHS U01 CA264583
6 · The paper itself

Abstract

Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens in normal tissues, as well as increased our understanding of the landscape of "field cancerization", that is, molecular and immune alterations in mutagen-exposed normal-appearing tissues that recapitulated those present in tumors. Charting the somatic mutational landscapes in normal tissues can have strong implications on our understanding of how tumors arise from mutagenized epithelium. Making sense of those mutations to understand the progression along the pathologic continuum of normal epithelia, preneoplasias, up to malignant tissues will help pave way for identification of ideal targets that can guide new strategies for preventing or eliminating cancers at their earliest stages of development. In this review, we will provide a brief history of field cancerization and its implications on understanding early stages of cancer pathogenesis and deviation from the pathologically "normal" state. The review will provide an overview of how mutations accumulating in normal tissues can lead to a patchwork of mutated cell clones that compete while maintaining an overall state of functional homeostasis. The review also explores the role of clonal competition in directing the fate of normal tissues and summarizes multiple mechanisms elicited in this phenomenon and which have been linked to cancer development. Finally, we highlight the importance of understanding mutations in normal tissues, as well as clonal competition dynamics (in both the epithelium and the microenvironment) and their significance in exploring new approaches to combatting cancer.

Indexed as

CarcinogenesisNeoplasmsClone CellsEpitheliumHumansMutationTumor Microenvironmentcancer evolutionClonal competitionField cancerizationField carcinogenesisSomatic mutations

Identifiers

PMID35850404
PMCPMC10249058
OpenAlexW4285606581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.